Iovance Biotherapeutics (IOVA) Projected to Post Earnings on Thursday

Key Points

• Iovance Biotherapeutics is set to release its Q2 2025 earnings after the market closes on August 7th, with analysts predicting (0.29) EPS and revenue of $67.14 million.
• In its previous quarterly earnings, Iovance reported ($0.36) EPS which was below analyst estimates, along with a revenue of $49.32 million.
• Analysts have adjusted their ratings on Iovance, with Baird R W and Truist Financial downgrading their ratings, while Chardan Capital maintained a "buy" rating with a price target of $25.00.

Iovance Biotherapeutics (NASDAQ:IOVA - Get Free Report) is anticipated to release its Q2 2025 earnings data after the market closes on Thursday, August 7th. Analysts expect Iovance Biotherapeutics to post earnings of ($0.29) per share and revenue of $67.14 million for the quarter. Iovance Biotherapeutics has set its FY 2025 guidance at EPS.

Iovance Biotherapeutics (NASDAQ:IOVA - Get Free Report) last announced its earnings results on Thursday, May 8th. The biotechnology company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.25) by ($0.11). The firm had revenue of $49.32 million during the quarter, compared to analysts' expectations of $83.40 million. Iovance Biotherapeutics had a negative net margin of 176.49% and a negative return on equity of 49.71%. Iovance Biotherapeutics's revenue for the quarter was up 6795.1% compared to the same quarter last year. During the same quarter last year, the company posted ($0.42) earnings per share. On average, analysts expect Iovance Biotherapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Iovance Biotherapeutics Stock Up 4.3%

Shares of Iovance Biotherapeutics stock traded up $0.11 on Friday, hitting $2.68. 16,645,574 shares of the company's stock traded hands, compared to its average volume of 25,143,334. The stock has a market cap of $894.93 million, a P/E ratio of -2.16 and a beta of 0.87. The firm's 50-day moving average is $2.14 and its 200 day moving average is $3.38. Iovance Biotherapeutics has a 52-week low of $1.64 and a 52-week high of $12.51.

Analyst Ratings Changes

Several equities analysts have recently commented on IOVA shares. The Goldman Sachs Group cut Iovance Biotherapeutics from a "neutral" rating to a "sell" rating in a research note on Tuesday, July 15th. Baird R W cut Iovance Biotherapeutics from a "strong-buy" rating to a "hold" rating in a research note on Friday, May 9th. Chardan Capital reaffirmed a "buy" rating and issued a $25.00 price objective on shares of Iovance Biotherapeutics in a report on Wednesday, July 23rd. Citizens Jmp downgraded shares of Iovance Biotherapeutics from an "outperform" rating to a "market perform" rating in a report on Friday, May 9th. Finally, Mizuho decreased their price objective on shares of Iovance Biotherapeutics from $30.00 to $10.00 and set an "outperform" rating for the company in a report on Monday, May 12th. Two analysts have rated the stock with a sell rating, six have assigned a hold rating and five have given a buy rating to the company's stock. According to data from MarketBeat.com, Iovance Biotherapeutics currently has a consensus rating of "Hold" and an average price target of $12.22.

Institutional Investors Weigh In On Iovance Biotherapeutics

Large investors have recently modified their holdings of the business. Royal Bank of Canada grew its holdings in shares of Iovance Biotherapeutics by 161.2% during the first quarter. Royal Bank of Canada now owns 522,887 shares of the biotechnology company's stock worth $1,740,000 after buying an additional 322,680 shares in the last quarter. AQR Capital Management LLC grew its holdings in shares of Iovance Biotherapeutics by 279.0% during the first quarter. AQR Capital Management LLC now owns 59,540 shares of the biotechnology company's stock worth $195,000 after buying an additional 43,829 shares in the last quarter. Goldman Sachs Group Inc. grew its holdings in shares of Iovance Biotherapeutics by 30.5% during the first quarter. Goldman Sachs Group Inc. now owns 5,571,902 shares of the biotechnology company's stock worth $18,554,000 after buying an additional 1,301,846 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of Iovance Biotherapeutics by 202.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,777,344 shares of the biotechnology company's stock worth $19,239,000 after buying an additional 3,869,617 shares in the last quarter. Finally, Envestnet Asset Management Inc. grew its holdings in shares of Iovance Biotherapeutics by 112.1% during the second quarter. Envestnet Asset Management Inc. now owns 47,466 shares of the biotechnology company's stock worth $82,000 after buying an additional 25,083 shares in the last quarter. 77.03% of the stock is currently owned by institutional investors.

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.